Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG miceopen access
- Authors
- Jeong, Hyemin; Kim, In Young; Bae, Eun-Kyung; Jeon, Chan Hong; Ahn, Kwang-Sung; Cha, Hoon-Suk
- Issue Date
- 7-Jun-2021
- Publisher
- Nature Publishing Group
- Citation
- Scientific Reports, v.11, no.1, pp 1 - 12
- Pages
- 12
- Journal Title
- Scientific Reports
- Volume
- 11
- Number
- 1
- Start Page
- 1
- End Page
- 12
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18789
- DOI
- 10.1038/s41598-021-91320-1
- ISSN
- 2045-2322
- Abstract
- Ankylosing spondylitis is a male-predominant disease and previous study revealed that estrogens have an anti-inflammatory effect on the spondyloarthritis (SpA) manifestations in zymosan-induced SKG mice. This study aimed to evaluate the effect of selective estrogen receptor modulator (SERM) lasofoxifene (Laso) on disease activity of SpA. Mice were randomized into zymosan-treated, zymosan+17 beta-estradiol (E2)-treated, and zymosan+Laso-treated groups. Arthritis was assessed by F-18-fluorodeoxyglucose (F-18-FDG) small-animal positron emission tomography/computed tomography and bone mineral density (BMD) was measured. Fecal samples were collected and 16S ribosomal RNA gene sequencing was used to determine gut microbiota differences. Both zymosan+E2-treated mice and zymosan+Laso-treated mice showed lower arthritis clinical scores and lower F-18-FDG uptake than zymosan-treated mice. BMD was significantly higher in zymosan+E2-treated mice and zymosan+Laso-treated mice than zymosan-treated mice, respectively. Fecal calprotectin levels were significantly elevated at 8 weeks after zymosan injection in zymosan-treated mice, but it was not significantly changed in zymosan+E2-treated mice and zymosan+Laso-treated mice. Gut microbiota diversity of zymosan-treated mice was significantly different from zymosan+E2-treated mice and zymosan+Laso-treated mice, respectively. There was no significant difference in gut microbiota diversity between zymosan+E2-treated mice and zymosan+Laso -treated mice. Laso inhibited joint inflammation and enhanced BMD in SKG mice, a model of SpA. Laso also affected the composition and biodiversity of gut microbiota. This study provides new knowledge regarding that selected SpA patients could benefit from SERM treatment.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.